CAR T Cell Therapy: A New Hope for Refractory Lupus?

Michael Alsharkawy(Oxford University Hospitals NHS Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Alice Mason(King's College Hospital), May Lwin(University Hospital Southampton NHS Foundation Trust)
touchREVIEWS in RMD
January 1, 2023
10.17925/rmd.2023.2.2.1
Cited by 2

Related Papers

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
|The Lancet|2021|324